Lactulose vs Rifaximin in Hepatic Encephalopathy
Lactulose is recommended as first-choice therapy for episodic overt hepatic encephalopathy (OHE). [1]
Rifaximin is recommended as an add-on to lactulose for secondary prophylaxis after a second OHE episode. [1]
Medication Selection Algorithm
Episodic Overt Hepatic Encephalopathy (Treatment of the Current Episode)
- Lactulose is selected as initial therapy for OHE. [1]
Secondary Prophylaxis (Prevention of Recurrence)
- Lactulose is continued after the initial OHE episode for prevention of recurrent OHE. [1]
- Rifaximin is added to lactulose after the second OHE episode for prevention of further recurrences. [1]
Rifaximin Monotherapy
- Rifaximin monotherapy is not supported by “solid data” and should not be used as the primary agent when lactulose is indicated. [1]
Treatment Initiation Thresholds
When Lactulose Is Used
- Lactulose is initiated for any episodic OHE (current event). [1]
When Rifaximin Is Added
- Rifaximin is added to lactulose for prevention of recurrent OHE after the second OHE episode. [1]
Monotherapy vs Combination Therapy
- Lactulose monotherapy is recommended for the initial (first) OHE prevention strategy after an initial episode. [1]
- Lactulose plus rifaximin is recommended for secondary prophylaxis after the second OHE episode. [1]
Dosing and Titration Targets Used Clinically
Lactulose
- Lactulose is titrated to achieve 2–3 bowel movements per day. [2]
Rifaximin
- Rifaximin 550 mg twice daily is used for hepatic encephalopathy. [3]
Key Evidence Supporting This Recommendation
- The AASLD/EASL guideline states that rifaximin is the best-documented add-on therapy to maintain remission in patients who have already experienced one or more OHE bouts while on lactulose. [1]
Common Pitfalls to Avoid
- Overtreatment with lactulose can cause complications such as aspiration, dehydration, hypernatremia, and severe perianal skin irritation. [1]
- Rifaximin should not be used as monotherapy when conventional lactulose-based management is indicated. [1]
Treatment Goals of Therapy
- The lactulose target is a regular stooling pattern (2–3 bowel movements per day) to suppress recurrent OHE. [2]
- The rifaximin goal is maintenance of remission and reduction of recurrent OHE when added after recurrent episodes. [1]